Comparative Pharmacology
Head-to-head clinical analysis: LODOCO versus PROBEN C.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LODOCO versus PROBEN C.
LODOCO vs PROBEN-C
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Colchicine binds to tubulin, inhibiting microtubule polymerization, which disrupts mitosis and reduces inflammatory cell chemotaxis, adhesion, and activation. It also inhibits NLRP3 inflammasome assembly and IL-1β production.
Probenecid inhibits tubular reabsorption of uric acid in the kidney, increasing uric acid excretion and lowering serum urate levels. It also competitively inhibits organic anion transport (OAT) at the proximal tubule, reducing renal excretion of penicillin and other beta-lactam antibiotics.
0.5 mg orally twice daily.
Oral, 500 mg twice daily. Each tablet contains probenecid 500 mg and colchicine 0.5 mg.
None Documented
None Documented
Terminal half-life: approximately 18-24 hours in patients with normal renal function.
Terminal elimination half-life of probenecid is approximately 6-12 hours in healthy adults; colchicine's terminal half-life ranges from 20-30 hours in normal renal function. Clinical context: Dosing interval adjustments are recommended in renal impairment (CrCl <50 mL/min) for colchicine accumulation risk.
Primarily renal (approximately 50-70% as unchanged drug), with biliary/fecal elimination accounting for 20-30%.
PROBEN-C (probenecid and colchicine) excretion: Probenecid is primarily excreted renally (75% as unchanged drug and metabolites), with a small amount excreted in bile (5-10%). Colchicine is eliminated mainly via feces (about 60% as unchanged drug and metabolites) and renal excretion (20-30%).
Category C
Category C
Antigout Agent
Antigout Agent